Citations

Clear

598 citation(s) found for "Foà, Alberto".

Remote patient management reduces liver-related hospitalizations in patients with acutely decompensated cirrhosis
Calleri, Alberto, Hara, Kamalpreet S. , Prusch Fernandes, Gabriel, Williams, Katherine M, Kloft-Nelson, Sara M, Leuenberger, Angela M, Sangaralingham, Lindsey R. , Rattan, Puru , Penrice, Daniel

Mayo Clinic

Hepatology | November 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001911 | PMID 43007295 Get It

Background: Patients with decompensated cirrhosis experience frequent hospitalizations, yet evidence supporting remote post-discharge care remains limited. This study assessed the impact of cirrhosis-specific Remote Patient Management (CiRPM) program following hospitalization for acutely decompensated (AD) cirrhosis. Methods: Adults hospitalized for AD cirrhosis were included in a three-cohort observational study comparing CiRPM (2021-2024) with contemporary (C-control) and historical controls (H-control, 2018-2019). CiRPM enabled vital-sign and symptom transmission with 24/7 virtual nursing support. Subgroup analyses were conducted by disease etiology, CLIF-C AD score, and decompensation type. IPTW was used to adjust for confounding, and time-to-event outcomes were analyzed using Cox proportional hazards models. Results: Among 430 patients (156 CiRPM, 152 H-control, 122 C-control), mean age was 59 years, 65% had alcohol-associated liver disease (ALD), CLIF-C AD score of 56. CiRPM was associated with lower 90-day liver-related readmissions versus C-control (39% vs. 58%; HR 0.57, p =0.01) and a similar trend versus H-control (39% vs. 52%; HR 0.67, p =0.07). Associations were stronger among patients with CLIF-C AD ≥60 (HR 0.43 vs. H-control, p =0.005; HR 0.51 vs. C-control, p =0.02). Among ALD patients, fewer fluid-related readmissions (OR 0.40 and 0.37; both p <0.001) and recurrent hospitalizations (OR 0.51; p =0.001 and p =0.002) were observed in the CiRPM group. In non-ALD patients, hepatic encephalopathy readmissions were lower (OR 0.29, p =0.004; OR 0.36, p =0.02). Mortality did not differ across groups. Conclusion: CiRPM enrollment was associated with fewer liver-related hospitalizations, particularly among patients with ALD and CLIF-C AD ≥60, supporting targeted remote management as a scalable post-discharge strategy for this high-risk population.
Real-World Phenobarbital Use, Treatment Escalation, and Clinical Outcomes in Critically Ill Patients With Alcohol Withdrawal Syndrome: A Multicenter Propensity-Matched Cohort Study
Rizwan, Zeeshan, Dierkhising, Ross, Stark, J , Schwarz, Jacob , Toufar, Sara, Marquez, Alberto , Rovati, Lucrezia , Gajic, Ognjen, Rizwan, Zeeshan M , Heybati, Kiyan , Stark, Jacqueline L, Gajic, Ognjen

Mayo Clinic

Critical Care Explorations | August 18, 2026 | Volume: 8 | Issue: 8 | Pages: e1466

10.1097/cce.0000000000001466 | PMID 42611632 Get It

IMPORTANCE: Phenobarbital use in ICU alcohol withdrawal syndrome (AWS) may reflect severe or refractory withdrawal and treatment escalation, making multicenter data important to understand its use within ICU practice and its relationship with clinical outcomes. OBJECTIVES: To evaluate phenobarbital use in real-world ICU AWS as a marker of severe or refractory withdrawal and treatment escalation. We also examined its association with time-to-discharge and safety outcomes compared with nonphenobarbital regimens. DESIGN, SETTING, AND PARTICIPANTS: Multicenter retrospective cohort study using multiple imputation and propensity score matching. Adults with AWS, defined as Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) score greater than or equal to 10, were included if they received a phenobarbital-based or nonphenobarbital-based regimen in ICUs across a large academic health system from June 30, 2017, to July 1, 2024. Postoperative ICU admissions were excluded. MAIN OUTCOMES AND MEASURES: Primary outcomes were time to ICU and hospital discharge alive from treatment initiation. Safety outcomes were hypotension, new intubation, and aspiration within 48 hours. RESULTS: Of 1216 patients, 345 (28.4%) received phenobarbital. Before matching, phenobarbital-treated patients had higher CIWA-Ar, Acute Physiology and Chronic Health Evaluation III, and pre-ICU benzodiazepine exposure, consistent with more severe or refractory withdrawal. In adjusted time-to-discharge models, phenobarbital use was not significantly associated with time to hospital discharge alive (discharge rate ratio [DRR], 0.91; 95% CI, 0.74–1.12; p = 0.370) or ICU discharge alive (DRR, 0.77; 95% CI, 0.59–1.01; p = 0.057). Hypotension and intubation were similar, and aspiration was less frequent with phenobarbital. CONCLUSIONS: In a contemporary ICU cohort, phenobarbital use reflected treatment escalation in patients with more severe or refractory AWS. After adjustment, time to ICU and hospital discharge alive did not differ significantly, hypotension and intubation were similar, and aspiration was less frequent with phenobarbital. Future studies should define optimal timing, dosing, and patient selection.
Online hemodiafiltration for kidney failure: guidance and best clinical practice recommendations from the Italian Society of Nephrology
Strippoli, Giovanni FM , Pellegrino, Giovanni, Hegbrant, J, Gallieni, Maurizio, Canaud, Bernard, Davenport, Andrew, Ortiz, Alberto, Malyszko, Jolanta, Kazancıoğlu, Rümeyza, Kuhlman, Martin, Ferreira, Ana Carina, Nigwekar, Sagar, Nissenson, Allen R, Nicola, Luca De, Strippoli, Giovanni F M , Lentini, Paolo Luca Maria, Hegbrant, Jörgen , Fabbrini, Paolo , Lentini, Paolo , Aucella, Filippo , Panichi, Vincenzo , Gallieni, Maurizio Alberto , Canaud, Bernard , Davenport, Andrew , Ramos, Rosa , Małyszko, Jolanta , Kazancioğlu, Rümeyza , Cromm, Krister , Nissenson, Allen R., Nicola, Luca De

Mayo Clinic

Journal of Nephrology | August 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/joneph/aajag225 | PMID 42614082 Get It

Abstract Background Online hemodiafiltration (HDF) enhances the removal of middle molecules, including large-middle molecules, through the combined action of diffusion and convection. Randomized controlled trials (RCTs) and individual participant data (IPD) meta-analyses demonstrate improved cardiovascular outcomes and, importantly, a reduction in all-cause mortality when HDF is delivered with sufficiently high convective volumes in post-dilution mode. These findings underscore that an adequate convective dose is a critical determinant of clinical benefits compared to high-flux hemodialysis (HD). However, translation into consistent clinical practice remains heterogeneous. Therefore, the Italian Society of Nephrology convened an international, multidisciplinary panel to synthesize randomized evidence comparing online post-dilution HDF with high-flux HD in adults receiving maintenance hemodialysis. Methods The critical outcomes included all-cause and cardiovascular mortality, whereas the important outcomes included selected patient-reported health domains, including physical function, patient-perceived cognitive function, pain interference, social participation, and health-related quality of life. The certainty of the evidence was appraised using the GRADE methodology. Structured guidance recommendations and best practice statements were developed through a consensus. Sensitivity analyses were performed to assess the robustness of the observed mortality effect. Results High-volume post-dilution HDF reduces all-cause mortality (hazard ratio 0.84; 95% CI 0 74–0.95; moderate-certainty evidence) and cardiovascular mortality (hazard ratio 0.78, 95% CI 0.64–0.96; moderate-certainty evidence; data from an individual participant data analysis of trials of high volume HDF versus high-flux HD). Emerging evidence suggests slower deterioration in selected patient-reported domains, including physical function, patient-perceived cognitive function, pain interference, and social participation (low-certainty evidence). Safety with on-line post-dilution HDF has been demonstrated to be similar to that of high-flux HD. Conclusions Online post-dilution HDF should be regarded as a dose-dependent therapy. We recommend its use to reduce cardiovascular mortality and suggest high-volume HDF to reduce all-cause mortality and slow deterioration in selected patient-reported health domains. Effective implementation in clinical practice requires a targeted and individualized approach with careful optimization and monitoring of convective volume, along with appropriate treatment time, blood-flow rate, supporting infrastructure, and consideration of patient preferences. This guidance provides evidence-based recommendations and best practice statements for its use.
Public health AI’s precision strategy: Globally integrating, institutionalizing, and scaling science, economics, and ethics
Anavekar, Nandan, Omutoko, Lillian , Oduor, Patience, Kokonya, Donald , Rayel, John James, Sotomayor, Claudia, Sinyavskiy, Oleg, Aksamit, Timothy, Marshall, Gary, Grindem, David, Jarsania, Dhairya, Mackay, K. , Garcia, Alberto, Gallagher, Colleen, Best, Ryan, Petralanda, Maria Isabel Iñigo, Immanuel, Gifty, Halm, Josiah, Iliescu, Cezar, Monlezun, Dominique , Anavekar, Nandan S., Oduor, Patience , Rayel, John, Sotomayor, Claudia , Aksamit, Timothy R. , Grindem, David , Jarsania, Dhairya , MacKay, Keir, Gallagher, Colleen M. , Dugani, Sagar B. , Best, Ryan, Gunasekeran, Dinesh Visva , Wong, Tien Yin , Halm, Josiah K. , Iliescu, Cezar

Mayo Clinic

No container title available | August 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10531187/v1 Get It

Abstract Artificial intelligence is spreading through public health agencies and healthcare systems faster than workforces are trained to govern it. We describe RHAMI (Responsible Health AI Readiness and Maturity Index), the first human-centered automated composite index for health organizations to score AI readiness and maturity as one measurable system of science, economics and ethics, and the physician certification-to-Master’s pathway built to teach what it measures—both designed jointly by frontline public health professionals, clinicians, ethicists, engineers, leaders, and policy-makers in low- and middle-income countries and high-income countries.
Sex differences in dementia pathology and cognitive performance in a population‐based, ethnically diverse Brazilian autopsy study
Socher, Karen Luiza Ramos , Paes, Vítor Ribeiro , Rodriguez, Roberta Diehl, Silva, Caroline Matos, Ururahy, Raul Reis, Moraes, Filipe Oto Cunha de , Padrão, Inês Liguori, Pasqualucci, Carlos, Nitrini, Ricardo, Grinberg, Lea Tenenholz, Leite, Renata Elaine Paraizo , Ferreira, Naomi Vidal , Justo, Alberto Fernando Oliveira , Rodriguez, Roberta Diehl , Ururahy, Raul dos Reis , Ferriolli, Eduardo , Nitríni, Ricardo , Grinberg, Lea T. , Brucki, Sônia Maria Dozzi , Suemoto, Cláudia Kimie

Mayo Clinic

Alzheimer's & Dementia | July 27, 2026 | Volume: 22 | Issue: 7 | Pages: No page available

10.1002/alz.71691 | PMID 42503573 Get It

Abstract INTRODUCTION Sex differences in dementia‐related neuropathology are understudied in diverse populations. METHODS We analyzed sex differences in neuropathological and cognitive data from the Brazilian Biobank for Aging Studies. Cognitive performance was evaluated with the Clinical Dementia Rating–Sum of Boxes (CDR‐SOB). Linear and logistic regression models were conducted, including interaction terms for age, race, and education. RESULTS In 2229 participants (50.7% female, mean age ± SD 75.4 ± 12.3 years, 62.1% White), female sex was associated with a higher odds of AD pathology (Braak: odds ratio [OR] = 1.42, 95% confidence interval [CI] = 1.17–1.72; Consortium to Establish a Registry for Alzheimer's Disease (CERAD): OR = 1.58, 95% CI = 1.27–1.98), and trans‐activation response (TAR) DNA‐binding protein 43 (TDP‐43) (OR = 1.77, IC 95% = 1.22–2.59), and lower odds of Lewy body disease (OR = 0.69, 95% CI = 0.51–0.95). Female participant had worse cognitive performance ( β = 1.56, 95% CI = 1.03–2.10). Sex modified associations of Braak, CERAD, TDP‐43, and cerebral amyloid angiopathy with cognition. Age also interacted with sex and pathology on CDR‐SOB. DISCUSSION Sex differences in the associations between sex and neuropathology suggest the need for sex‐informed dementia research.
Bridging Conservative Management With Injectable Orthobiologic Therapies: Proceedings of the International Consensus Meetings on Cartilage Repair of the Ankle
Tham, Alexander, Rubin, Jared, Butler, James J., Gauthier, Paloma , Kennedy, John G. , Adams, Samuel B., Andrews, Carol L., Batista, Jorge , Baur, Onno L., Bayer, Stephen, Becher, Christoph, Berlet, Gregory C. , Boakye, Lorraine AT, Buda, R, Calder, James D. F., Dahmen, Jari , D’Hooghe, Pieter, DiGiovanni, Christopher W., Ehlers, M. , Ferkel, Richard D. , Ferkel, Eric, Ferrao, Paulo N. F., Giza, Eric , Gianakos, Arianna L., Glazebrook, Mark, Gomaa, Mohamed, Görtz, Simon, Haleem, Amgad M. , Hamid, Kamran S. , Hangody, László, Haverkamp, Daniel, Hertel, Jay, Hintermann, Beat, Hogan, MaCalus V., Hunt, Kenneth J., Hurley, Eoghan T., Karlsson, Jon, Kearns, Stephen R. , Kerkhoffs, Gino M. M. J., Kim, Hak Jun , Kong, Siu Wah, Krebsbach, Sebastian, Labib, Sameh A. , Lambers, Kaj T. A. , Lee, Jin Woo, Lee, Keun Bae, Ling, Jeffrey S., Longo, Umile Giuseppe, Marangon, Alberto, McCollum, G, McCullough, Kirk, Mittwede, Peter N. , Murawski, Christopher D. , Nicolescu, Raluca, Niemeyer, Philipp, Nunley, James A., O'Malley, Martin, Ortiz, Cristian, Osei-Hwedieh, David O. , Paul, Jochen , Pearce, Christopher J., Pereira, Hélder , Phadke, Rohan , Prado, Marcelo P. , Raikin, Steven M., Reilingh, Mikel L., Robert, Guillaume , Lc, Schon, Simpson, Helene, Smyth, Niall A. , Sofka, Carolyn M., Spennacchio, Pietro, Stone, James W., Takao, M, Tanaka, Yasuhito, Thermann, Hajo, Thordarson, David B. , Rs, Tuan, Valderrabano, Victor, Bergen, Christian J. A. van, Dijk, Pim A. D van, Dijk, Niek van, Vannini, Francesca, Vaseenon, Tanawat , Volesky, Monika , Walls, Raymond C., Walther, Markus, Wiewiorski, Martin, Xu, Xiangyang, Yasui, Youichi , Yinghui, Hua, Yoshimura, Ichiro, Younger, Alastair , Zdanowicz, Urszala, Zhang, Zijun, Adams, Samuel B. , Clanton, Thomas O , Dahmen, Jari , Ehlers, Mallory , Hannon, Charles P , Labib, Sameh A , Popchak, Adam , Robert, Guillaume , Smyth, Niall A , Tham, Alexander , Rubin, J Peter , Butler, James J., Angthong, Chayanin , Becher, Christoph, Boakye, Lorraine A. T. , Buda, Roberto , Calder, James D. F. , Canata, Gian Luigi , Carreira, Dominic S. , Dahmen, Jari , d’Hooghe, Pieter P. R. N. , DiGiovanni, Christopher William , Dombrowski, Malcolm E. , Ferkel, Eric I. , Ferrao, Paulo N. F. , Gianakos, Arianna L. , Glazebrook, Mark Anthony , Gomaa, Mohamed, Hannon, Charles P. , Haverkamp, Daniël , Hintermann, Beat , Hogan, MaCalus Vinson , Hunt, Kenneth John , Hurley, Eoghan T. , Karlsson, Jon, Kerkhoffs, Gino M. M. J. , Krebsbach, Sebastian , Lee, Jin Woo , Longo, Umile Giuseppe , Mitchell, Adam W. , Nehrer, Stefan , Niemeyer, Philipp , Nunley, James A. , O’Malley, Martin , Pearce, Christopher Jon , Pereira, Hélder , Raikin, Steven M. , Rothrauff, Benjamin B. , Schon, Lew Charles , Spennacchio, Pietro , Sullivan, Martin, Tanaka, Yasuhito , Valderrábano, Víctor , Dijk, Pim A. D. van , Vannini, Francesca , Walther, Markus , Wiewiorski, Martin J., Xu, Xiangyang , Yoshimura, Ichiro , Zhang, Zijun

Mayo Clinic

Foot & Ankle Specialist | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/19386400261456925 | PMID 42495946 Get It

Background The management of osteochondral lesions of the talus (OLT) is challenging, with 2 main options being conservative and surgical management. Orthobiologic therapies come to bridge the gap between these 2 options; however, inconsistencies in indication, composition, and heterogeneous evidence limit clinical decision-making. To address these challenges, 3 International Congress Meetings on Cartilage Repair of the Ankle were convened in Pittsburgh, USA (2017), Dublin, Ireland (2019), and New York, USA (2025) to establish agreement on the role of conservative management and injectable orthobiologic strategies in the treatment of OLT. Methods Seventy-five multidisciplinary experts from over 25 countries and 1 territory participated in a structured Delphi-based consensus process. Blinded surveys, structured questionnaires, and in-person discussions were used to develop and refine statements, supported by literature review and graded evidence (A1–E). Consensus strength was defined as consensus (51%-74%), strong consensus (75%-99%), or unanimous (100%) Results In total, 29 consensus statements were achieved across the 3 meetings. Strong agreement was reached regarding indications and expected outcomes of conservative management, including the role of immobilization and appropriate timing for surgical intervention. Orthobiologic injections, including platelet-rich plasma, concentrated bone marrow aspirate, and hyaluronic acid, were considered appropriate in select patients with persistent symptoms, although no superiority was demonstrated among formulations, preparation methods, or injection strategies. When used as adjuncts to surgical procedures, orthobiologics may improve radiological outcomes, with limited evidence for improvement in clinical outcomes. Technical considerations, including preferred harvest sites and a lack of standardized preparation protocols, were identified, along with key principles for patient counseling Conclusion These international consensus statements establish a standardized framework for the conservative management and use of injectable orthobiologic therapies in OLT. By clarifying indications, technical considerations, and current limitations, this work aims to improve consistency in clinical practice, guide treatment decision-making, and inform future research.
Consensus on biomarker utility for ACTH-dependent Cushing syndrome: a Pituitary Society Modified Delphi Panel
Fleseriu, Maria , Biller, Beverly M. K. , Reincke, Martín , Мелмед, Шломо , Group, the Pituitary Society International Cushing Syndrome Delphi Panel Consensus, Akirov, Amit , Araki, Takako, Auchus, Richard, Ben-Shlomo, Anat , Bertherat, Jérôme, Biermasz, Nienke R, Castinetti, Frédéric, Ceccato, Filippo, Christ-Crain, Mirjam, Feelders, Richard A. , Findling, James W. , Gadelha, Monica, Geer, Eliza B, Giustina, Andrea, Grossman, Ashley, Gurnell, Mark, Hanzu, Felicia, Hinojosa-Amaya, Jose M, Isand, Kristina , Isidori, Andrea M, Kadioğlu, Pinar, Karavitaki, Niki, McCormack, A I, Nieman, Lynnette, Nowak, Elisabeth, Pivonello, Rosario, Salvatori, Roberto , Stewart, Paul M., Tabarin, Antoine, Takahashi, Yutaka, Theodoropoulou, Marily , Valassi, Elena, Varlamov, Elena V , Walia, Rama, Wass, John, Cheung, Cassandra, Priven, Mariel , Brown, Marielle, Biller, Beverly M K , Bancos, Irina , Fukuoka, Hidenori , Reincke, Martin , Newell-Price, John , Melmed, Shlomo , Bancos, Irina , Newell‐Price, John , Bertherat, Jérôme , Bidlingmaier, Martin , Biermasz, Nienke Ruurdje , Castinetti, Frédéric , Ceccato, Filippo , Christ‐Crain, Mirjam , Gadelha, Mônica R. , Geer, Eliza B. , Glezer, Andréa , Giustina, Andrea , Greenman, Yona , Grossman, Ashley, Gurnell, Mark , Hanzu, Felicia Alexandra , Hinojosa‐Amaya, José Miguel , Isidori, Andrea M. , Kadıoğlu, Pınar , Karavitaki, Niki , Langlois, Fabienne , Nieman, Lynnette K. , Nowak, Elisabeth , Pereira, Alberto M. , Petersenn, Stephan , Pivonello, Rosario , Tabarin, Antoine , Valassi, Elena , Vila, Greisa , Brown, Marielle, Fleseriu, Maria

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1210/clinem/dgag279 | PMID 42460773 Get It

Abstract Context Biochemical test results are central to clinical decision-making for the diagnosis and management of Cushing syndrome (CS). With emerging research and increasing availability of different tests, updated consensus on the utility of these biomarkers is warranted. Objective To establish an updated consensus on the role of biomarkers in the diagnosis and monitoring of adrenocorticotropic hormone-dependent CS, address novel therapeutic approaches, and identify areas for future research. Design A modified 2-round Delphi panel was conducted. Consensus was defined as ≥70% agreement/disagreement for Likert-scale statements or ≥70% selection of the same option for single-choice questions. Setting Participants represented a range of international expertise. Participants Forty-one participants took part in the Delphi panel, with no attrition between rounds (one nonclinician was not required to complete the second round). An 8-member Steering Committee guided statement development. Results Of statements designed to reach consensus, 45% (14/31) and 44% (11/25) statements reached consensus in Rounds 1 and 2, respectively. Notably, most panelists reported the use of late-night salivary cortisol for diagnosis of mild CS and for monitoring following pituitary surgery or medical or radiation therapy. Most panelists responded that block-and-replace therapies can be considered in patients with cyclical or severe CS, and consensus was reached that restoration of circadian rhythm is a treatment goal for patients with CS. Conclusion Areas of alignment among experts on the diagnosis and monitoring of CS are presented. The findings from this study are intended to support clinicians in their clinical decision-making and highlight priority areas for future research.
Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure
Vernetti, Patricio Millar , Palma, Jose‐Alberto , Shibao, Cyndya A. , Freeman, Roy , Gibbons, Christopher H. , Singer, Wolfgang , Coon, Elizabeth A. , Miglis, Mitchell G. , Krismer, Florian , Fanciulli, Alessandra , Millar Vernetti, Patricio , Biaggioni, Italo , Shibao, Cyndya A , Freeman, Roy L. , Gibbons, Christopher , Singer, Wolfgang , Coon, Elizabeth Anne , Miglis, Mitchell G , Krismer, Florian , Fanciulli, Alessandra , Goldstein, David S. , Betensky, Rebecca A. , Kaufmann, Horacio , Palma, Jose-Alberto

Mayo Clinic

Movement Disorders | July 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/mds.70417 | PMID 42444112 Get It

Abstract Background The Movement Disorder Society (MDS) research criteria for possible prodromal multiple system atrophy (PP‐MSA) have not been prospectively validated. Objective To evaluate the diagnostic performance of the PP‐MSA criteria in a longitudinal cohort of patients with pure autonomic failure (PAF) and to assess whether additional clinical features improve their predictive value. Methods Seventy‐six patients with PAF enrolled across eight centers in the Natural History Study of the Synucleinopathies were followed for ≥6 years or until phenoconversion. Participants were classified according to MDS PP‐MSA criteria and followed for development of MSA, Parkinson's disease, or dementia with Lewy bodies. Diagnostic performance was assessed longitudinally. Analyses were repeated using a stricter olfactory threshold (University of Pennsylvania Smell Identification Test [UPSIT]≤28) as an exclusion criterion. Results Thirty‐eight participants met PP‐MSA criteria, of whom 12 phenoconverted to MSA within 6 years. Sensitivity was 100% at year 1 and 92% at year 6, whereas specificity ranged from 56% to 67%. Positive predictive value (PPV) ranged from 21% to 34%. Applying a stricter olfactory threshold improved specificity (90%–97%) and PPV (53%–83%), with a modest reduction in sensitivity (to 83%). Participants who phenoconverted to MSA were younger, had more severe urinary dysfunction, and greater orthostatic heart rate responses. Conclusions The PP‐MSA criteria demonstrate high sensitivity but limited specificity in patients with PAF. A stricter olfactory threshold improves diagnostic performance and may enhance cohort enrichment for clinical trials. © 2026 International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease
Soleimani‐Meigooni, David N. , Chiotis, Konstantinos, Allen, Isabel E., Rabinovici, Gil D., Joie, Renaud La , Group, Meta-Centiloid Study, Apostolova, Liana G. , Asken, Breton M., Benzinger, Th., Betthauser, Tobey J., Bluma, Marina, Bombois, Stephanie, Bourgeat, Pierrick, Bouteloup, Vincent , Braskie, Meredith N., Brendel, Matthias, Brickman, Adam M., Bryant, Natalie, Bullich, Santiago , Carrillo, Maria C., Casaletto, Kaitlin, Cash, David M., Chang, Chiung-Chih, CHANG, H L, Chao, Yishu , Collij, Lyduine E., Corrada, Maria M., Craft, Suzanne , Dickerson, Bradford C., Dubois, Bruno, Dufouil, Carole, Fajardo, Alfonso, Farrar, Gill , Fortea, Juan, Frings, Lars , Frisoni, Giovanni B., Gardner, Raquel C., Gnörich, Johannes , Gordon, Brian A., Gu, Yuna , Guan, Yihui, Guo, Tengfei, Hanseeuw, Bernard J., Hansson, Oskar, Harrison, Theresa M., Huang, Qi, Huang, ST , Iaccarino, Leonardo, Ishii, Kazunari, Ishi, Kenji, Jagust, William J., Johnson, Sterling C., Kato, Takashi, Katsumi, Yuta, Kaye, Jeffrey, Kolinger, Guilherme D., Kramer, Joel H. , Landau, Susan M., Landeau, Brigitte, Lao, Patrick J., Lee, Sangwon, Lopresti, Brian J., Lowe, Val J. , Luchsinger, José A., Mao, Xiaoxie, March, Andrew, Masters, Colin L., Meyer, Philipp T., Mezenge, Florence, Mormino, Elizabeth C., Franquesa‐Mullerat, María , Nakamura, Akinori, Nordberg, Agneta, O’Brien, John T., O’Bryant, Sid E., Pappas, Ioannis, Peretti, Debora E., Rowe, Christopher C., Rowe, James B., Schwartz, Daniel L., Seo, Sang Won , Shekari, Mahnaz, Smith, Ruben, Snyder, Heather M. , Sokolowski, Andrzej, Sperling, Reisa A., Sun, Pan, Taggett, Jacinda Z., Touroutoglou, Alexandra , Vaillancourt, David E., Giessen, Elsmarieke van de, Vijverberg, Jort, Villemagne, Victor L. , Villeneuve, Sylvia , Wang, Wei-en, Weiner, Michael, Woodworth, Davis, Xiao, Cally , Xie, F, Yoon, Yeojun, Yun, Mijin, Severanc, A4, ABIDE, ADNI*, ADNI-DoD, AgeWell, AIBL, AMYPAD, BACS, BATON, BIOCARD, BLSA, BioFINDER-2, BrANCH, CPAS, DETECT-AD, GEMS, GHABS, HABS, HABS-HD, IDEAS, IMAP, INSIGHT-preAD, Insight46, K-ROAD, LEADS, MCSA, MULNIAD, MEMENTO, SCAN, PREVENT-AD, SPIN,, Corrada, María M. , La Joie, Renaud , Blazhenets, Ganna , Chiotis, Konstantinos , Allen, Isabel Elaine , Rabinovici, Gil D. , Asken, Breton M. , Bejanin, Alexandre , Benzinger, Tammie L.S. , Betthauser, Tobey J. , Blūma, Marina , Bombois, Stéphanie , Bourgeat, Pierrick , Braskie, Meredith N. , Brendel, Matthias , Brickman, Adam M. , Carrillo, María C. , Casaletto, Kaitlin B. , Cash, David M. , Chang, Chiung‐Chih , Chang, Hsin‐I , Chêne, Geneviève , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Bradford Clark , Dubois, Bruno , Dufouil, Carole , Fortea, Juan , Garibotto, Valentina , Gordon, Brian A. , Guan, Yihui , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Iaccarino, Leonardo , Ishii, Kazunari , Ishii, Kenji, Jagust, William J. , Johnson, Sterling C. , Katsumi, Yuta , Kaye, Jeffrey , Koeppe, Robert A. , Kolinger, Guilherme Domingues , Landau, Susan , Landeau, Brigitte , Lao, Patrick , Lee, Sangwon, Lleó, Alberto , Lopresti, Brian J. , Malpetti, Maura , March, Andrew, Masters, Colin L. , Mézenge, Florence, Mormino, Elizabeth C. , Nakamura, Akinori , Nordberg, Agneta , O'Brien, John Tiernan , O’Bryant, Sid E. , Pappas, Ioannis , Quenon, Lisa , Rowe, Christopher Cleon , Rowe, James B. , Rudolph, Marc D. , Salvadó, Gemma , Schott, Jonathan M. , Schwarz, Christopher G. , Shekari, Mahnaz , Silbert, Lisa C. , Smith, Ruben, Sokolowski, Andrzej, Sperling, Reisa Anne , Sun, Pan , Taggett, Jacinda , Toga, Arthur W. , Vaillancourt, David E. , Giessen, Elsmarieke van de , Vemuri, Prashanthi , Villain, Nicolas , Wang, Wei‐en , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Yun, M R

Mayo Clinic

JAMA | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.13116 | PMID 42441390 Get It

Importance Amyloid positron emission tomography (PET) is increasingly used in research and clinical settings to determine the etiology of cognitive decline and eligibility for amyloid-targeting therapies. To assist with amyloid PET evaluation and to guide clinical decision-making, images can be quantified in a standardized unit called Centiloid, the interpretation of which can vary according to the method and threshold used. Objective To collect Centiloid values from available studies and determine robust positivity cutoffs using data-driven methods and correspondence with visual reads. Data Sources PubMed search (October 2024) identified studies with Centiloid values. Corresponding authors were invited to share individual participant data. Additional data were obtained through access-controlled repositories and conference outreach (July 2024-July 2025). Study Selection Studies were included if they provided Centiloids, radiotracer, age, and sex. Data Extraction and Synthesis Each study was analyzed using a unified statistical pipeline; study estimates were pooled using random-effects meta-analysis. Main Outcomes and Measures Gaussian mixture models (GMMs) were fitted to Centiloid values for each study. In studies with a bimodal distribution (per integrated completed likelihood), single cutoffs for positivity were set as mean plus 2 SDs of the lower gaussian component. Using GMMs, a double-cutoff approach defined a lower certainty range using a 90% posterior probability cutoff for assignment to the low (amyloid-negative) vs high (amyloid-positive) component. An alternative Centiloid cutoff was derived from maximizing the correspondence (Cohen κ) with the binary visual reads when available. Results This meta-analysis included cross-sectional amyloid PET scans acquired with 5 radiotracers from 49 227 participants across 53 studies from 15 countries (mean age, 71 years; 54% female, 62% cognitively impaired). The data-driven GMM approach identified a bimodal distribution in 51 studies (n = 48 786), resulting in a single cutoff for positivity of 18 Centiloids (95% CI,16-19; I 2 = 97%). The double-cutoff approach revealed high confidence for interpreting scans as negative when Centiloid values were lower than 11 (95% CI, 9-13; I 2 = 95%) and interpreting scans as positive if Centiloid values were higher than 26 (95% CI, 24-28; I 2 = 95%). In analyses of correspondence with binary (positive or negative) visual reads of amyloid PET scans (n = 35 045; 36 studies), Centiloids were highly predictive of visual positivity (Cohen κ, 0.86; 95% CI, 0.83-0.89; I 2 = 96%) with a cutoff of 27 Centiloids (95% CI, 24-30; I 2 = 80%). Conclusions and Relevance In this individual participant data meta-analysis, positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads). Findings from a double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use.
Safety and performance of small bowel capsule endoscopy in patients with surgically altered gastrointestinal anatomy
Naseem, Zehra, Prado, Renan, Aggarwal, Manik, Nasser, Jason, Wu, Yueqi, Yang, Qijun, McMichael, John, Kundu, Rupayan, Funk, Cynthia, Ford, Andrew, Simons-Linares, C. Roberto, Naseem, Zehra , Kaul, Ridhima , Chatterjee, Arjun , Aggarwal, Manik , Yang, Qijun , Kundu, Rupayan , Ford, Andrew M. , Simons-Linares, C. Roberto , Rubio‐Tapia, Alberto

Mayo Clinic

Scandinavian Journal of Gastroenterology | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.1080/00365521.2026.2696878 | PMID 42390964 Get It